Akshat Jain: Reassessing Cost-Effectiveness of Iron Deficiency Anemia Treatments
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn about his recent article published in Blood Advances:
”Happy to share our New Publication in Blood Advances.
We address an important question in the management of iron deficiency anemia (IDA) and the interpretation of health economics bringing global burden of this significant health morbidity per World Health Organization.
While recent modeling suggested that first-line intravenous (IV) iron may be the most cost-effective strategy for women with heavy menstrual bleeding, our publication emphasizes that cost-effectiveness is only as strong as the assumptions and comparators included in the model and real world avalaibility of these treatment options.
Key scientific messages from this publication:
- Calls for cautious interpretation of cost-effectiveness models that rely on uncertain assumptions regarding adherence, quality-of-life estimates, and long-term outcomes.
- Highlights the omission of ferric carboxymaltose (FCM)—one of the most widely used contemporary IV iron formulations—which may substantially influence both healthcare costs, new risks of bone health and patient outcomes.
- Brings a global health perspective to the discussion, recognizing that in many low- and middle-income countries, oral iron remains the only practical and affordable treatment option because of resource and infrastructure limitations.
- Encourages future comparative economic studies that include contemporary IV iron formulations while accounting for regional healthcare realities before translating modeling results into universal clinical policy.
Scientific progress depends not only on new discoveries but also on thoughtful evaluation of the evidence that guides patient care.
As healthcare systems increasingly rely on economic modeling to shape policy, ensuring that these analyses are comprehensive, globally relevant, and clinically applicable is essential.
Proud to contribute to this important discussion in hematology and healtheconomics.”
Title: Iron Deficiency: Cost-Effectiveness and Global Applicability
Authors: Akshat Jain
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 4, 2026, 18:57Connecting Haemophilia Centres, Certifying Treaters, and Improving National Data in Romania – EHC
-
Nov 4, 2026, 18:45Smitirupa Mishra: A Practical Guide to Coagulation Pathway Assessment and Laboratory Interpretation
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A
-
Nov 4, 2026, 15:20Augustina Isioma Ikusemoro: Before You Transfuse, Think PBM
-
Nov 4, 2026, 14:23Advancing Hemophilia Care Through Global Research – WFH
-
Nov 4, 2026, 14:12Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
-
Nov 4, 2026, 13:59Rita Li: ASH 2026 Abstract Achievement Award for Gut Microbiome Research
-
Nov 4, 2026, 13:38Omid Seidizadeh: Improving Access to von Willebrand Disease Diagnosis and Treatment Across Europe